bpc-157 adverse event case report FDA panel votes to place popular peptide on compounding list BPC 157 (Body Protection Compound-157)

Response: Although we acknowledge the applicant's concerns regarding the descriptor for C1739, we do not agree that the device category code should be withdrawn and replaced with a new code effective January 1, 2026, for the following reasons: First, per the applicant's request prior to CY 2026 rulemaking, CMS revised the descriptor for C1739 to read, effective October 1, 2025: Tissue marker, uniquely detectable and identifiable with probe/sensor, any method (implantable), with delivery system

Riojas, M

BPC 157 was used in the same regular regimens (10 g or 10 ng/kg, per-orally/intragastrically), shown to be effective in all BPC 157 studies (5, 9)

It is a fundamental limitation of preclinical research

doi: 10.1016/j.reprotox.2013.01.002 10 SchugTTJanesickABlumbergBHeindelJJ